News & Events


Cosmetic treatment indicated to counteract hair loss and thinning

Fidia Farmaceutici held a press conference last week, to announce the imminent release of the Trinov Anti-hair loss Lotion to Italian pharmacies. Designed to contrast hair loss in women and men, the Anti-hair loss Lotion is based on an innovative patented formula consisting of phospholipid liposomes…
Fidia farmaceutici announces the results of a prospective clinical investigation aimed at assessing the effectiveness and the safety of Hydeal-D vaginal pessaries, composed of an ester of hyaluronic acid, in the treatment of vulvovaginal atrophy in post-menopause women. - Vulvovaginal atrophy in…


• Completion of efficacy and tolerability study
• Full-scale production initiated
• Launch in Italy by the end of 2018

Further to previous communications, regarding the development of a hair loss remedy (aka “Brotzu lotion”) initiated several months ago, we are pleased to announce the completion of the efficacy and tolerability study, following an intensive research program. The study was conducted productively and…

The acquisition gives an added boost to Fidia’s leadership in the national and international ophthalmology market segment

• Sooft is active in the treatment of all major eye conditions through Sooft, Bioos, Glaucoom, OftaH.T.and Neoox trademarks
• The company owns 27 patents, further bolstering Fidia Pharma Group’s already strong portfolio, consisting of more than 1,100 patents, of which over 700 on hyaluronic acid

Abano Terme (PD), June 11, 2018 – Fidia Pharma Group, an Italian multinational company, leader in the R&D, manufacturing and sales of a wide range of products mainly based on hyaluronic acid, announced today the closing of the acquisition of Sooft, #1 Italian ophthalmic company in Italy , by…

Poster Title: “Hyaluronan Derivative Hymovis® Increases Cartilage Volume and Type II Collagen Turnover in Osteoarthritis Knee:
Data from MOKHA (MRI, BiOmarkers, Knee, Hymovis®, OsteoArthritis) Study”

• Potential beneficial effect of HYMOVIS® on pain and function
• Structural modifying effect in knee OA with HYMOVIS®

Abano Terme, Italy, April 25, 2018 – Fidia Farmaceutici, a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announce that new data will be presented at the Osteoarthritis Research Society…


Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint healthcare
- ophthalmology
- wound care
- dermatology
- neurology
- dermo-aesthetics